International Journal of Radiation Oncology*Biology*Physics
Novel Imaging for Treatment PlanningAn Automated Multiparametric MRI Quantitative Imaging Prostate Habitat Risk Scoring System for Defining External Beam Radiation Therapy Boost Volumes
Introduction
Radiation dose escalation improves control of intermediate- to high-risk prostate cancer, with doses above 80 Gy improving outcomes (1). Limiting the highest radiation doses to the gross tumor volume (GTV), as opposed to whole prostate, is hypothesized to result in equivalent tumor control without increasing side effects 2, 3, 4. A major obstacle is defining the GTV in a systematic and reproducible way. Although the use of multiparametric (mp) magnetic resonance imaging (MRI) for GTV identification is gaining momentum because of its diagnostic reliability for distinguishing intraprostatic tumors with a Gleason score (GS) of 7 or greater 5, 6, there is considerable variability in how boost volumes are defined. Currently, the Prostate Imaging, Reporting and Diagnosis System (PIRADS) is the standard of care for region of interest (ROI) identification and risk classification 7, 8. However, there is subjectivity in PIRADS; the system was not designed for 3-dimensional (3D) volume assessment, a wealth of quantitative information in mpMRI is ignored, and PIRADS does not accurately and reproducibly elucidate inter- and intralesional spatial heterogeneity.
In this report, a quantitative mpMRI analysis technique that combines perfusion (dynamic contrast enhanced [DCE]) and diffusion mpMRI sequences to identify distinct pathophysiologic regions, or Habitats (9), is described. In 2 prior reports, we described (1) DCE-Score (10) and (2) apparent diffusion coefficient (ADC) thresholds and volumes to describe risk based on GS. We describe herein a pixel-by-pixel habitat risk scoring (HRS) system that combines the quantitative DCE and ADC information by referencing a prostatectomy data set. The automatically generated heat maps were used prospectively to guide radiation therapy (RT) boost volumes in a randomized phase 2 clinical trial, BLaStM, comparing 2 methods of increasing dose to the mpMRI-defined tumor habitat region(s).
Section snippets
Patients
For the development of the prostate mpMRI analysis techniques, the institutional review board approved a protocol for retrospective review of patients who have undergone prostate mpMRI. Patients who underwent radical prostatectomy (RP) during 2016 and had an mpMRI done using the 3T Discovery MR750 magnet (GE, Waukesha, WI) were identified. The institutional review board waived the need for informed consent for the prostatectomy cohort. The BLaStM clinical trial was open for accrual in February
HRS
HRS was calculated in 12 prostatectomy patients with available mpMRI preoperatively, using η1 = 0.8 and η2 = 0.2 for TZ and η1 = 0.5 and η2 = 0.5 for PZ; ε = 0.01 cm3. The ability of HRS to discriminate between cancer versus no cancer, GS ≥7 versus no cancer, and GS = 6 and GS ≥8 versus no cancer or GS = 6 or 7 was compared with PIRADS4/5 in 51 tumor nodules (26 GS ≥7 and 25 GS = 6) (Table E1; available online at https://doi.org/10.1016/j.ijrobp.2018.06.003). The HRS algorithm had a higher
Discussion
Prostate cancer radiation dose escalation improves clinical outcomes, and there is evidence that doses beyond 80 Gy result in substantive improvements 1, 21. However, when the whole prostate is dose escalated, there is an increase in the risk of grade 3 complications (22). An alternative approach is to dose escalate beyond 80 Gy only to determinate tumor areas in the prostate. Although multiple groups 2, 3, 4 have sought to direct radiation dose to such high-risk tumor regions in lieu of
Conclusions
An automated quantitative method was developed to identify habitats in the prostate determinate with the potential to be determinate of outcome. The HRS system assigns risk pixel by pixel in mpMRI sequences and was referenced to prostatectomy. The HRS6 contour was associated with GS risk and was then used to guide RT boost volumes.
References (25)
- et al.
Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT Trial): An analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer
Int J Radiat Oncol Biol Phys
(2017) - et al.
Boosting imaging defined dominant prostatic tumors: A systematic review
Radiother Oncol
(2013) - et al.
Radiotherapy boost for the dominant intraprostatic cancer lesion—A systematic review and meta-analysis
Clin Genitourin Cancer
(2016) - et al.
Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature
Eur Urol
(2015) - et al.
PI-RADS prostate imaging – Reporting and data system: 2015, Version 2
Eur Urol
(2016) - et al.
What dose of external-beam radiation is high enough for prostate cancer?
Int J Radiat Oncol Biol Phys
(2007) - et al.
ASCENDE-RT: An analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a edose-escalated external beam boost for high- and intermediate-risk prostate cancer
Int J Radiat Oncol Biol Phys
(2017) - et al.
Single blind randomized phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): Study protocol for a randomized controlled trial
Trials
(2011) - et al.
Multiparametric MRI for prostate cancer localization in correlation to whole-mount histopathology
J Magn Reson Imaging
(2013) - et al.
ESUR prostate MR guidelines 2012
Eur Radiol
(2012)
Quantitative imaging in cancer evolution and ecology
Radiology
Automatic detection and quantitative DCE-MRI scoring of prostate cancer aggressiveness
Front Oncol
Cited by (15)
The Promise and Future of Radiomics for Personalized Radiotherapy Dosing and Adaptation
2023, Seminars in Radiation OncologyPhase I Trial of MRI-Guided Prostate Cancer Lattice Extreme Ablative Dose (LEAD) Boost Radiation Therapy
2020, International Journal of Radiation Oncology Biology PhysicsCitation Excerpt :The resultant workflow has been incorporated into a randomized phase II trial (NCT02307058; The BLaStM trial)47; the LEAD treatments in the BLaStM trial are administered on a standard linear accelerator, making the workflow more generalizable.
This work was supported by National Institutes of Health (grant numbers R01CA189295 and R01CA190105).
Conflict of interest: none
Supplementary material for this article can be found at https://doi.org/10.1016/j.ijrobp.2018.06.003.